Public Employees Retirement Association of Colorado lessened its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 4.2% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 21,082 shares of the biotechnology company’s stock after selling 929 shares during the period. Public Employees Retirement Association of Colorado’s holdings in BioMarin Pharmaceutical were worth $1,841,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Lindbrook Capital LLC boosted its stake in BioMarin Pharmaceutical by 259.8% during the fourth quarter. Lindbrook Capital LLC now owns 385 shares of the biotechnology company’s stock worth $37,000 after buying an additional 278 shares during the period. Benjamin F. Edwards & Company Inc. boosted its stake in BioMarin Pharmaceutical by 135.3% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 433 shares of the biotechnology company’s stock worth $42,000 after buying an additional 249 shares during the period. Jones Financial Companies Lllp purchased a new position in BioMarin Pharmaceutical during the fourth quarter worth $43,000. First Horizon Advisors Inc. boosted its stake in BioMarin Pharmaceutical by 33.3% during the fourth quarter. First Horizon Advisors Inc. now owns 576 shares of the biotechnology company’s stock worth $56,000 after buying an additional 144 shares during the period. Finally, Allworth Financial LP boosted its stake in BioMarin Pharmaceutical by 54.9% during the fourth quarter. Allworth Financial LP now owns 604 shares of the biotechnology company’s stock worth $58,000 after buying an additional 214 shares during the period. Institutional investors own 98.71% of the company’s stock.
BioMarin Pharmaceutical Price Performance
Shares of NASDAQ:BMRN opened at $84.07 on Tuesday. BioMarin Pharmaceutical Inc. has a twelve month low of $73.68 and a twelve month high of $99.56. The company’s 50 day moving average is $81.89 and its 200 day moving average is $85.31. The company has a current ratio of 2.74, a quick ratio of 1.70 and a debt-to-equity ratio of 0.12. The company has a market cap of $15.96 billion, a PE ratio of 78.57, a price-to-earnings-growth ratio of 1.20 and a beta of 0.32.
Wall Street Analyst Weigh In
Check Out Our Latest Research Report on BioMarin Pharmaceutical
Insider Buying and Selling
In other BioMarin Pharmaceutical news, EVP George Eric Davis sold 1,850 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $85.01, for a total value of $157,268.50. Following the sale, the executive vice president now owns 56,157 shares in the company, valued at approximately $4,773,906.57. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CFO Brian Mueller sold 5,000 shares of the stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $75.19, for a total transaction of $375,950.00. Following the transaction, the chief financial officer now owns 72,159 shares in the company, valued at approximately $5,425,635.21. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP George Eric Davis sold 1,850 shares of the stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $85.01, for a total value of $157,268.50. Following the transaction, the executive vice president now owns 56,157 shares in the company, valued at approximately $4,773,906.57. The disclosure for this sale can be found here. In the last quarter, insiders have sold 67,700 shares of company stock worth $5,209,352. 1.85% of the stock is owned by company insiders.
BioMarin Pharmaceutical Profile
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Further Reading
- Five stocks we like better than BioMarin Pharmaceutical
- Investing in Commodities: What Are They? How to Invest in Them
- Has Micron’s Stock Drop Turned Into A Screaming Buy?
- What Are Dividends? Buy the Best Dividend Stocks
- Should You Invest in Bonds? Here’s What to Know
- What is the FTSE 100 index?
- Why This Manufacturer is Committing to a Massive Buyback Program
Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.